Pentraxin 3 in the cerebrospinal fluid during central nervous system infections: A retrospective cohort study

PLoS One. 2023 Mar 2;18(3):e0282004. doi: 10.1371/journal.pone.0282004. eCollection 2023.

Abstract

The present study describes diagnostic and prognostic abilities of Cerebrospinal fluid (CSF) Pentraxin 3 (PTX3) in central nervous system (CNS) infections. CSF PTX3 was measured retrospectively from 174 patients admitted under suspicion of CNS infection. Medians, ROC curves and Youdens index was calculated. CSF PTX3 was significantly higher among all CNS infections and undetectable in most of the patients in the control group, and significantly higher in bacterial infections compared to viral and Lyme infections. No association was found between CSF PTX3 and Glasgow Outcome Score. PTX3 in the CSF can distinguish bacterial infection from viral and Lyme infections and non-CNS infections. Highest levels were found in bacterial meningitis. No prognostic abilities were found.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • C-Reactive Protein
  • Central Nervous System Infections*
  • Humans
  • Lyme Disease*
  • Retrospective Studies

Substances

  • PTX3 protein
  • C-Reactive Protein

Grants and funding

Receiver of grant: MMT Funder: Nordsjællands Hospital Url: https://www.nordsjaellandshospital.dk/forskning/Sider/default.aspx The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.